Portal de investigación
Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Ribera, JM
- Morgades, M
- Martino, R
- Barba, P
- Soria, B
- Bermudez, A
- Moreno, MJ
- Gonzalez-Campos, J
- Vives, S
- Gil, C
- Abella, E
- Guàrdia R
- Martinez-Carballeira, D
- Martinez-Sanchez, P
- Amigo, ML
- Mercadal, S
- Serrano, A
- Lopez-Martinez, A
- Vall-Llovera, F
- Sanchez-Sanchez, MJ
- Peñarrubia MJ
- Calbacho, M
- Mendez, JA
- Bergua, J
- Cladera, A
- Tormo, M
- Garcia-Belmonte, D
- Feliu, E
- Ciudad, J
- Orfao, A
- PETHEMA Group, Spanish Society of Hematology
Grupos
Abstract
Native or pegylated (PEG) asparaginase (ASP) are commonly used in treatment of acute lymphoblastic leukemia (ALL), but have been scarcely compared in the same trial in adult patients. Native vs. PEG-ASP administered according to availability in each center were prospectively evaluated in adults with high-risk ALL. Ninety-one patients received native ASP and 35 PEG-ASP in induction. No significant differences were observed in complete remission, minimal residual disease levels after induction and after consolidation, disease-free survival, and overall survival. No significant differences in grades 3-4 toxicity were observed in the induction period, although a trend for higher hepatic toxicity was observed in patients receiving PEG-ASP. In this trial the type of ASP did not influence patient response and outcome.
Datos de la publicación
- ISSN/ISSNe:
- 1042-8194, 1029-2403
- Tipo:
- Article
- Páginas:
- 1634-1643
- PubMed:
- 29165013
- Factor de Impacto:
- 1,013 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
LEUKEMIA & LYMPHOMA TAYLOR & FRANCIS LTD
Citas Recibidas en Web of Science: 16
Documentos
- No hay documentos
Filiaciones
Keywords
- Adult acute lymphoblastic leukemia; Escherichia coli asparaginase; native; pegylated; efficacy; toxicity
Campos de Estudio
Cita
Ribera JM,Morgades M,MONTESINOS P,Martino R,Barba P,Soria B,Bermudez A,Moreno MJ,Gonzalez J,Vives S,Gil C,Abella E,Guàrdia R,Martinez D,Martinez P,Amigo ML,Mercadal S,Serrano A,Lopez A,Vall F,Sanchez MJ,Peñarrubia MJ,Calbacho M,Mendez JA,Bergua J,Cladera A,Tormo M,Garcia D,Feliu E,Ciudad J,Orfao A,PETHEMA SSOH. Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk. Lymphoma. 2018. 59. (7):p. 1634-1643. IF:2,674. (3).